Wei P, Zhang Z H, Li L, Du X L, Shan C P, Sheng X G
Department of Gynecologic Oncology, Shandong Tumor Hospital and Institute, Jinan, Shandong Province, China.
Department of Occupational Health and Occupational Medicine Institute, Jinan, Shandong Province, China.
Genet Mol Res. 2015 Apr 22;14(2):3833-42. doi: 10.4238/2015.April.22.12.
This retrospective study aimed to observe the cura-tive effect and adverse reactions of three-dimensional conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent epithelial ovarian carcinoma. The chemoradiotherapy group (N = 22) received 15 mv X-rays with 1.8 to 2.0 Gy/f/d radiation, 5 times per week. The total dose was 45 to 65 Gy; the median dose was 52.5 Gy. Topotecan chemotherapy (2.0 mg/m(2)) was administered after the first week of radiotherapy on days 1, 8, and 15; it was repeated every 28 days. The only che-motherapy group (N = 20) received topotecan chemotherapy (4.0 mg/m(2)) in the first week, and the dose was administered on days 1, 8, and 15; it was repeated every 28 days. The median follow-up times were 18.5 months (2 to 37.7) and 10.8 months (1.5 to 29.6) in the chemoradiotherapy and in the only chemotherapy groups, respectively. The total response rates were 42.1% (8/19) and 11.1% (2/18), respectively. The clinical benefit rates were 68.4% (13/19) and 22.2% (4/18), respectively, with significant difference (P < 0.05). The median disease progression-free periods were 9.8 and 6.6 months, respectively, with significant difference (P < 0.001). The median survival times were 19.7 and 12.5 months, respective-ly, with significant difference (P < 0.05). The degrees of digestive tract reaction rates were 26.3% (5/19) and 16.7% (3/18), whereas the hematology toxicity rates were 21.1% (4/19) and 22.2% (4/18), respectively, with no significant difference (P > 0.05). As three-dimensional conformal radiotherapy combined with topotecan che-motherapy had good curative effect on platinum-resistant recurrent epithelial ovarian cancer, with mild adverse reactions, this tech-nique can be used as a remedial measure.
本回顾性研究旨在观察三维适形放疗联合拓扑替康化疗治疗铂耐药复发性上皮性卵巢癌患者的疗效及不良反应。放化疗组（N = 22）接受15兆伏X线，照射剂量为1.8至2.0 Gy/次/天，每周5次。总剂量为45至65 Gy；中位剂量为52.5 Gy。放疗第1周后的第1、8和15天给予拓扑替康化疗（2.0 mg/m²）；每28天重复1次。单纯化疗组（N = 20）在第1周接受拓扑替康化疗（4.0 mg/m²），剂量在第1、8和15天给予；每28天重复1次。放化疗组和单纯化疗组的中位随访时间分别为18.5个月（2至37.7个月）和10.8个月（1.5至29.6个月）。总缓解率分别为42.1%（8/19）和11.1%（2/18）。临床受益率分别为68.4%（13/19）和22.2%（4/18），差异有统计学意义（P < 0.05）。中位无疾病进展期分别为9.8个月和6.6个月，差异有统计学意义（P < 0.001）。中位生存时间分别为19.7个月和12.5个月，差异有统计学意义（P < 0.05）。消化道反应发生率分别为26.3%（5/19）和16.7%（3/18），血液学毒性发生率分别为21.1%（4/19）和22.2%（4/18），差异无统计学意义（P > 0.05）。由于三维适形放疗联合拓扑替康化疗对铂耐药复发性上皮性卵巢癌疗效良好，不良反应轻微，该技术可作为一种补救措施。
